Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
批准号:
9763356
负责人:
AARON HAMVAS
金额:
$57.82万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2021-06-30
关键词:
AffectAgeAlgorithmsAutonomic nervous systemBiological MarkersBronchopulmonary DysplasiaCardiacCardiovascular PhysiologyCardiovascular systemCerebrovascular PhysiologyCerebrumChemoreceptorsChildChronicClinicalComorbidityDevelopmentDiagnosticDiseaseDisease OutcomeDocumentationEarly identificationFamilyFutureHealth Care CostsHospitalizationHourHypoxiaImpairmentIndividualInfantInfant DevelopmentInterventionLate pregnancyLifeLungLung diseasesMeasurementMeasuresMedical RecordsMethodsMonitorMorbidity - disease rateMotorNeonatalNervous System PhysiologyNeurologicOutcomeOutcome MeasureOxygenPathogenesisPatternPeripheralPharmaceutical PreparationsPhysiologic MonitoringPhysiologicalPregnancyPremature BirthPremature InfantRegulationReportingResearchResolutionRiskRoleSensorySeveritiesStratificationTestingTimebasecerebrovascularclinical applicationinnovationinsightmembernervous system developmentneural circuitnovel strategiesphysiologic modelprematureprospectiveresiliencerespiratoryresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The broad long-term objective of the proposed study is to use comprehensive state-of-the-art high-fidelity
monitoring to investigate physiological biomarkers of autonomic neurorespiratory maturation with integrated
analysis of autonomic nervous system (ANS) responses in preterm infants, and to evaluate their role in
ventilatory instability, bronchopulmonary dysplasia (BPD), and co-morbidities including impaired neuromotor
development in the 1st year of life. SPECIFIC AIM 1 will establish the spectrum and developmental trajectory of
ANS maturation/function using 20-hour high-resolution recordings of ventilatory, cardiovascular, and
cerebrovascular physiology during typical endogenous daily activity (32 and 36 weeks; 3 months) and brief
evoked hypoxic, hyperoxic, and hypercarbic challenges of peripheral and central chemoreceptors to unmask
latent autonomic and respiratory instability (36 weeks; 3 and 12 months). Aim 1 tests the hypothesis that
individual and integrated metrics of ANS function will demonstrate maturational patterns that impart resilience
or vulnerability to physiologic challenges. SPECIFIC AIM 2 will determine respiratory and neurodevelopmental
morbidity throughout the 1st year of life using a composite Respiratory Morbidity Severity Score that includes
need for respiratory support, medications, or hospitalization (3, 6, 9, 12 months), and the Neurological,
Sensory, Motor, Developmental Assessment (3, 6, 12 months) as clinically applicable outcome measures, and
will associate these measures with ANS development and function. Aim 2 tests the hypothesis that infants
demonstrating delayed ANS maturation or vulnerability to physiologic perturbations will require more
respiratory interventions and will demonstrate neuromotor delays in the 1st year of life. SPECIFIC AIM 3 will
determine endotypes of autonomic neurorespiratory stability and maturation through trajectory analysis and
integrated physiological modeling. Aim 3 tests the hypothesis that trajectory analysis will reveal 3 autonomic
maturation patterns (1)anticipated maturation with ability to withstand physiologic perturbations; 2)anticipated
maturation without ability to withstand physiologic perturbations; and 3)delayed or disordered maturation with
an inability to maintain physiologic stability even in the absence of environmental perturbations) that will predict
varying degrees of respiratory morbidity and neuromotor impairment at 1 year. This novel approach will
establish the role of autonomic neurorespiratory maturation in stability of oxygenation throughout the 1st year of
life, provide insight into BPD pathogenesis, allow prospective identification of at-risk infants, and permit
development of mechanism-specific interventions that have potential to impact thousands of families and
billions of dollars in healthcare costs each year in the U.S., alone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neonatal Research Network: the Lurie Children's - Northwestern University Study Center
-
批准号:10682322
-
项目类别:
-
资助金额:$33.12万
-
财政年份:2023
-
负责人:AARON HAMVAS
-
依托单位:
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
-
批准号:9170046
-
项目类别:
-
资助金额:$19.1万
-
财政年份:2016
-
负责人:AARON HAMVAS
-
依托单位:
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
-
批准号:10006025
-
项目类别:
-
资助金额:$53.06万
-
财政年份:2016
-
负责人:AARON HAMVAS
-
依托单位:
PROGRESSIVE LUNG DISEASE AND SURFACTANT DYSFUNCTION WITH A DELETION OF SURFACT
-
批准号:7355212
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2006
-
负责人:AARON HAMVAS
-
依托单位:
PULMONARY DYSFUNCTION & INTEGRITY OF PULMONARY SURFACTANT SYSTEM
-
批准号:7180070
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2005
-
负责人:AARON HAMVAS
-
依托单位:
PROGRESSIVE LUNG DISEASE AND SURFACTANT DYSFUNCTION WITH A DELETION OF SURFACT
-
批准号:7180175
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2005
-
负责人:AARON HAMVAS
-
依托单位:
PULMONARY DYSFUNCTION & INTEGRITY OF PULMONARY SURFACTANT SYSTEM
-
批准号:6977040
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2003
-
负责人:AARON HAMVAS
-
依托单位:
In Vivo Metabolism of Pulmonary Surfactant in Infants
-
批准号:6331907
-
项目类别:
-
资助金额:$26.96万
-
财政年份:2001
-
负责人:AARON HAMVAS
-
依托单位:
In Vivo Metabolism of Pulmonary Surfactant in Infants
-
批准号:6537856
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:AARON HAMVAS
-
依托单位:
In Vivo Metabolism of Pulmonary Surfactant in Infants
-
批准号:6886704
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:AARON HAMVAS
-
依托单位:
In Vivo Metabolism of Pulmonary Surfactant in Infants
-
批准号:6745959
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:AARON HAMVAS
-
依托单位:
In Vivo Metabolism of Pulmonary Surfactant in Infants
-
批准号:6638678
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2001
-
负责人:AARON HAMVAS
-
依托单位:
MONITORING SURFACTANT USE IN THE NEONATAL INTENSIVE CARE UNIT
-
批准号:6244126
-
项目类别:
-
资助金额:$2.25万
-
财政年份:1997
-
负责人:AARON HAMVAS
-
依托单位:
MONITORING SURFACTANT USE IN THE NEONATAL INTENSIVE CARE UNIT
-
批准号:5215764
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:AARON HAMVAS
-
依托单位:--
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: